Gabapentin Tablet, Film Coated
Product Images NDC 60687-518

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 60687-518). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

600 mg Blister

Gabapentin 600 mg film-coated tablets label by American Health Packaging. The image shows a sheet of multiple label stickers including the drug name, strength (600 mg), dosage form (tablet, film coated), barcodes, expiration and lot number placeholders, and the labeler information from American Health Packaging, Columbus, Ohio.*

FDA Label Image

600 mg Carton

Label for Gabapentin 600 mg film-coated tablets, oral use, supplied by American Health Packaging. The label indicates packages containing 100 tablets (10 x 10) with the NDC 60687-507-01. It includes dosage information, storage instructions, pharmacist dispensing guidance, and safety warnings. The manufacturer is Zydus Pharmaceuticals (USA) Inc.*

FDA Label Image

800 mg Blister

Label sheet showing multiple identical labels for Gabapentin Tablet, USP 800 mg, film-coated oral tablets. Each label includes barcodes, space for lot number and expiration date, and the American Health Packaging labeler information from Columbus, Ohio.*

FDA Label Image

800 mg Carton

Label for Gabapentin tablets, USP 800 mg, film-coated, oral dosage form. The label shows a package size of 100 tablets (10 x 10) and is marked Rx Only. Labeler is American Health Packaging. The label includes instructions for pharmacists to dispense with a medication guide and storage temperature guidelines between 20° to 25°C with permitted excursions. It also warns to keep out of reach of children and not to use if blister is broken.*

FDA Label Image

Ahp50701

Gabapentin 600 mg film-coated oral tablet, white to off-white, capsule-shaped with the imprint 'ZE 72' on one side and a scored line on the other. The tablet is uncoated on the reverse side and intended for oral use. Labeler: American Health Packaging.*

FDA Label Image

Ahp51801

Gabapentin 800 mg film-coated oral tablet, oval and white with a scored line. One side is imprinted with 'ZE 71', while the other side is plain with a scored line. The product is manufactured by American Health Packaging.*

FDA Label Image

Equation

A mathematical formula illustrating the calculation for creatinine clearance (CLCr), incorporating variables for age, weight, serum creatinine levels, and a factor for female patients. The formula is presented in a fraction with a multiplier, reflecting pharmacokinetic considerations relevant to drug dosing.*

FDA Label Image

Figure 1

A line graph showing mean pain scores over eight weeks comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin group's pain scores decrease over time, while placebo remains relatively stable.*

FDA Label Image

Figure 2

A line graph showing mean pain scores over 7 weeks comparing placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents time in weeks from baseline to week 7, while the y-axis shows mean pain scores from 0 to 10. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period, with both gabapentin doses showing a greater reduction in mean pain scores compared to placebo.*

FDA Label Image

Figure 3

A bar chart depicting comparative results from two studies evaluating Gabapentin (GBP) versus placebo (PBO). Study 1 compares PBO at 12% with GBP 3600 mg at 29%, indicating statistical significance (p < 0.01). Study 2 compares PBO at 14% with GBP 1800 mg at 32% and GBP 2400 mg at 34%, both showing higher values with stronger statistical significance (p < 0.001). The vertical axis is percentage-based from 0% to 100%, illustrating increased outcome measures with higher Gabapentin doses.*

FDA Label Image

Figure 4

A scatter plot chart showing difference (%) on the vertical axis and daily dose (mg) on the horizontal axis. It compares data points from three studies (STUDY a, STUDY b, STUDY c) at various gabapentin daily doses: 600 mg, 900 mg, 1200 mg, and 1800 mg. Each study is represented by different colored squares as indicated in the legend on the right.*

FDA Label Image

Structure

Chemical structure diagram of gabapentin, showing its cyclohexane ring with amino and acetic acid functional groups attached.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.